drugset
drugset / Trial / NCT02009423

Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence

NCT02009423 ↗

Phase 3 Terminated 7 enrolled AB Science
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective is to compare the efficacy and safety of masitinib at 4.5 mg/kg/day to placebo in the treatment of patients with localized, primary gastrointestinal stromal tumor (GIST) after complete surgery and with high risk of recurrence.

Timeline

Start
2015-07
Primary completion
2015-11
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Masitinib Small molecule 4.5 mg/kg —

Indications

gastrointestinal stromal tumor